drugset / Trial / NCT06434103
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer
Timeline
- Start
- 2024-10-10
- Primary completion
- 2024-10-10
- Completion
- 2024-10-10
Outcome
Outcome not reported
Stopped (Business): “Sponsor's Strategy Adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | SHR-A1921 | Monoclonal antibody | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | SHR-8068 | Monoclonal antibody | — | — |